NASDAQ: ILMNIllumina Inc Stock
$136.48-7.74 (-5.37%)
Updated Jan 14, 2025
Illumina shares are trading lower... find out Why ILMN Price Moved with a free WallStreetZen account
Why Price MovedILMN Price
$136.48
Fair Value Price
$55.48
Market Cap
$21.65B
52 Week Low
$100.09
52 Week High
$156.66
P/E
-13.72x
P/B
10.19x
P/S
4.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.39B
Earnings
-$1.58B
Gross Margin
63.9%
Operating Margin
-32.8%
Profit Margin
-36.1%
Debt to Equity
1.83
Operating Cash Flow
$697M
Beta
1.09
Next Earnings
Feb 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ILMN Overview
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ILMN's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Value
B
Growth
C
Momentum
B
Sentiment
B
Safety
A
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
ILMN
Ranked#2 of 56
Ranked#2 of 56
Be the first to know about important ILMN news, forecast changes, insider trades & much more!
ILMN News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ILMN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ILMN ($136.48) is overvalued by 145.98% relative to our estimate of its Fair Value price of $55.48 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ILMN ($136.48) is not significantly undervalued (145.98%) relative to our estimate of its Fair Value price of $55.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ILMN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ILMN due diligence checks available for Premium users.
Valuation
ILMN fair value
Fair Value of ILMN stock based on Discounted Cash Flow (DCF)
Price
$136.48
Fair Value
$55.48
Overvalued by
145.98%
ILMN ($136.48) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ILMN ($136.48) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ILMN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ILMN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.72x
Industry
23.75x
Market
30.21x
ILMN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.19x
Industry
4.09x
ILMN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ILMN's financial health
Profit margin
Revenue
$1.1B
Net Income
$705.0M
Profit Margin
65.3%
ILMN's Earnings (EBIT) of -$1.44B... subscribe to Premium to read more.
Interest Coverage Financials
ILMN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.0B
Liabilities
$3.9B
Debt to equity
1.83
ILMN's short-term assets ($2.37B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ILMN's long-term liabilities ($2.91B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ILMN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ILMN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$316.0M
Investing
-$41.0M
Financing
-$332.0M
ILMN's operating cash flow ($697.00M)... subscribe to Premium to read more.
Debt Coverage Financials
ILMN vs Diagnostic & Research Stocks
Illumina Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.